Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Uncontrolled, Open-label, Evaluation of Lamotrigine Monotherapy in Newly Diagnosed Epilepsy or Recurrent Epilepsy (Currently Untreated)

NCT01431963 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01431963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01431963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Uncontrolled, Open-label, Evaluation of Lamotrigine Monotherapy in Newly Diagnosed Epilepsy or Recurrent Epilepsy (Currently Untreated)
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2011
Completion date
October 31, 2014
Enrollment
70 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy